公开(公告)号：US20160145298A1

公开(公告)日：2016-05-26

申请号：US14946866

申请日：2015-11-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： YAT SUN OR ,  Jun Ma ,  Guoqiang Wang ,  Jiang Long ,  Bin Wang

IPC: C07K5/12

Abstract: The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20160145296A1

公开(公告)日：2016-05-26

申请号：US14952526

申请日：2015-11-25

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Ruichao Shen ,  Peng Dai ,  Jiang Long ,  Xuechao Xing ,  Guoqiang Wang

IPC: C07J43/00 ,  C07J31/00 ,  C07J9/00 ,  C07J41/00

CPC classification number: C07J43/003 ,  A61P1/16 ,  C07J9/00 ,  C07J9/005 ,  C07J17/00 ,  C07J31/006 ,  C07J41/0055 ,  C07J41/0061 ,  C07J41/0088 ,  C07J41/0094 ,  C07J51/00

Abstract: The present invention relates to compounds of Formula (IA) and Formula (IB), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.

Abstract translation: 本发明涉及式（IA）和式（IB）的化合物及其药学上可接受的盐，其中R1，R2，R3，R4，R5，R6，R7，R8，R9和m如本文所定义，药物组合物 包括这些化合物和这些化合物用于治疗TGR5介导的疾病或病症的方法。

公开(公告)号：US20150056165A1

公开(公告)日：2015-02-26

申请号：US14469403

申请日：2014-08-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Guoqiang Wang ,  Jiang Long ,  In Jong Kim

IPC: C07K7/64 ,  A61K38/13 ,  A61K45/06

CPC classification number: A61K38/13 ,  A61K38/00 ,  A61K38/21 ,  A61K45/06 ,  C07K7/645 ,  Y02A50/463 ,  A61K2300/00

Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

Abstract translation: 本发明涉及对HCV具有抗病毒活性的新型环孢菌素类似物，可用于治疗HCV感染。 更具体地，本发明涉及新的环孢菌素类似物化合物，含有这些化合物的组合物及其使用方法，以及制备这些化合物的方法。

公开(公告)号：US20140194350A1

公开(公告)日：2014-07-10

申请号：US14146161

申请日：2014-01-02

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Jun Ma ,  Guoqiang Wang ,  Jiang Long ,  Bin Wang

IPC: A61K38/12 ,  C07K5/097

CPC classification number: C07K5/123 ,  A61K38/00 ,  A61K38/12 ,  A61K45/06 ,  C07K5/06034 ,  C07K5/0808 ,  C07K5/0823 ,  C07K5/0827 ,  C07K14/811

Abstract: The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20130183267A1

公开(公告)日：2013-07-18

申请号：US13734074

申请日：2013-01-04

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Guoqiang Wang ,  Jiang Long ,  Xuri Gao

IPC: C07K7/52 ,  A61K38/21 ,  A61K31/7088 ,  A61K38/13 ,  A61K45/00

CPC classification number: A61K38/13 ,  A61K31/7088 ,  A61K38/21 ,  A61K45/00 ,  A61K45/06 ,  C07K7/52 ,  C07K7/645 ,  Y02A50/463

Abstract: The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

Abstract translation: 本发明涉及对HCV具有抗病毒活性的环孢菌素类似物，可用于治疗HCV感染。 更具体地，本发明涉及新的环孢菌素类似物化合物，含有这些化合物的组合物及其使用方法，以及制备这些化合物的方法。